Global Blood Therapeutics Inc. (GBT)

47.99
1.50 3.20
NASDAQ : Health Technology
Prev Close 46.49
Open 46.85
Day Low/High 46.70 / 48.64
52 Wk Low/High 30.15 / 64.94
Volume 573.60K
Avg Volume 767.30K
Exchange NASDAQ
Shares Outstanding 60.02M
Market Cap 2.79B
EPS -3.40
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

GBT To Host Analyst & Investor Day On October 8 In New York

GBT To Host Analyst & Investor Day On October 8 In New York

SOUTH SAN FRANCISCO, Calif., Oct.

Sector Liquidations Provide Great Opportunity but Short Term Pain Is Tremendous

Sector Liquidations Provide Great Opportunity but Short Term Pain Is Tremendous

There is no respite today from the poor price action in individual stocks.

GBT Announces Participation At The 2019 Cantor Global Healthcare Conference

GBT Announces Participation At The 2019 Cantor Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Sept.

GBT Announces U.S. Food And Drug Administration Acceptance Of New Drug Application And Priority Review For Voxelotor For The Treatment Of Sickle Cell Disease

GBT Announces U.S. Food And Drug Administration Acceptance Of New Drug Application And Priority Review For Voxelotor For The Treatment Of Sickle Cell Disease

Priority Review Shortens FDA Review Time to Six Months from Standard 10 Months NDA Supported by Data from Phase 3 HOPE Study, which Demonstrated Statistically Significant and Sustained Improvements in Hemoglobin with Voxelotor SOUTH SAN FRANCISCO, Calif.

GBT Announces New Employment Inducement Grants

GBT Announces New Employment Inducement Grants

SOUTH SAN FRANCISCO, Calif., Sept.

GBT Announces Participation At The 2019 Morgan Stanley Global Healthcare Conference

GBT Announces Participation At The 2019 Morgan Stanley Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Sept.

GBT And Sickle Cell Disease Association Of America To Host 8th Annual Sickle Cell Disease (SCD) Therapeutics Conference

GBT And Sickle Cell Disease Association Of America To Host 8th Annual Sickle Cell Disease (SCD) Therapeutics Conference

Patient Advocates, Healthcare Providers and Policy Makers to Discuss the Latest Advances and Future Trends for Treating Patients with SCD Conference Taking Place During National Sickle Cell Awareness Month Livestream of Conference will be Available...

GBT Reports Recent Business Progress And Second Quarter 2019 Financial Results

GBT Reports Recent Business Progress And Second Quarter 2019 Financial Results

SOUTH SAN FRANCISCO, Calif., Aug.

GBT Announces Participation At The 2019 Wedbush PacGrow Healthcare Conference

GBT Announces Participation At The 2019 Wedbush PacGrow Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Aug.

GBT Announces New Employment Inducement Grants

GBT Announces New Employment Inducement Grants

SOUTH SAN FRANCISCO, Calif., Aug.

GBT And Advocates Launch Disease Awareness Campaign Focused On Breaking Down Stigmas Associated With Sickle Cell Disease

GBT And Advocates Launch Disease Awareness Campaign Focused On Breaking Down Stigmas Associated With Sickle Cell Disease

Company Also Launches Disease Awareness Campaign to Raise Awareness Among Physicians About the Silent Damage Caused by Sickle Cell Disease

GBT Announces New Employment Inducement Grants

GBT Announces New Employment Inducement Grants

SOUTH SAN FRANCISCO, Calif., July 09, 2019 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc.

SS&C Increases Offer On Non-Binding Indicative Proposal To Acquire GBST Holdings Limited

SS&C Increases Offer On Non-Binding Indicative Proposal To Acquire GBST Holdings Limited

WINDSOR, Conn., July 3, 2019 /PRNewswire/ -- SS&C Technologies Holdings, Inc.

SS&C Enters Into Non-Binding Indicative Proposal To Acquire GBST Holdings Limited

SS&C Enters Into Non-Binding Indicative Proposal To Acquire GBST Holdings Limited

WINDSOR, Conn., July 1, 2019 /PRNewswire/ --  SS&C Technologies Holdings, Inc.

Notable Monday Option Activity: GBT, AKS, BOLD

Notable Monday Option Activity: GBT, AKS, BOLD

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Global Blood Therapeutics Inc , where a total of 4,413 contracts have traded so far, representing approximately 441,300 underlying shares. That amounts to about 51.3% of GBT's average daily trading volume over the past month of 859,935 shares.

Noteworthy Thursday Option Activity: GBT, AMBC, ANF

Noteworthy Thursday Option Activity: GBT, AMBC, ANF

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Global Blood Therapeutics Inc , where a total of 3,147 contracts have traded so far, representing approximately 314,700 underlying shares. That amounts to about 49.1% of GBT's average daily trading volume over the past month of 641,280 shares.

I Like These 2 Smaller Name Biotech Stocks

I Like These 2 Smaller Name Biotech Stocks

I still believe it will be a big year for buyouts across the biotech industry.

The Fed and Trump Are Both Wrong: Cramer's 'Mad Money' Recap (Tuesday 12/4/18)

The Fed and Trump Are Both Wrong: Cramer's 'Mad Money' Recap (Tuesday 12/4/18)

Markets looking for reassurance aren't getting any from the White House or the Federal Reserve, Jim Cramer says.

Interesting GBT Put And Call Options For June 2019

Interesting GBT Put And Call Options For June 2019

Investors in Global Blood Therapeutics Inc saw new options become available this week, for the June 2019 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 239 days until expiration the newly available contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

INVESTIGATION ALERT: The Schall Law Firm Announces It Is Investigating Claims Against Global Blood Therapeutics, Inc. And Encourages Investors With Losses In Excess Of $100,000 To Contact The Firm

INVESTIGATION ALERT: The Schall Law Firm Announces It Is Investigating Claims Against Global Blood Therapeutics, Inc. And Encourages Investors With Losses In Excess Of $100,000 To Contact The Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Global Blood Therapeutics, Inc.

EQUITY ALERT: Rosen Law Firm Announces Investigation Of Securities Claims Against Global Blood Therapeutics, Inc. - GBT

EQUITY ALERT: Rosen Law Firm Announces Investigation Of Securities Claims Against Global Blood Therapeutics, Inc. - GBT

Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Global Blood Therapeutics, Inc.

Noteworthy Thursday Option Activity: GBT, CARA, COUP

Noteworthy Thursday Option Activity: GBT, CARA, COUP

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Global Blood Therapeutics Inc , where a total volume of 2,914 contracts has been traded thus far today, a contract volume which is representative of approximately 291,400 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 42% of GBT's average daily trading volume over the past month, of 693,765 shares.

3 Biotech Stocks Ready to Burn Up

3 Biotech Stocks Ready to Burn Up

Biotechs are known for wild tears. Investors, you'll want to consider these drug makers.

Fear of Missing Out Outweighs Fear of Trump Political Fallout

Fear of Missing Out Outweighs Fear of Trump Political Fallout

If the market wanted an excuse to sell off it had it.

Strength in Growth Names Is Giving the Market a More Upbeat Feel

Strength in Growth Names Is Giving the Market a More Upbeat Feel

Apple in particular is helping the bullish cause.

Heineken Stock Boosted By China Deal as Jefferies Downgrades

Heineken Stock Boosted By China Deal as Jefferies Downgrades

If there is any good news on trade the potential for more market upside is strong.

First Week Of GBT March 2019 Options Trading

First Week Of GBT March 2019 Options Trading

Investors in Global Blood Therapeutics Inc saw new options become available this week, for the March 2019 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 233 days until expiration the newly available contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.